RS 2102
Alternative Names: RS-2102Latest Information Update: 28 Sep 2026
At a glance
- Originator Reistone Biopharma
- Developer Jiangsu Hengrui Medicine Co.; Reistone Biopharma
- Class Anti-inflammatories; Interleukins; Proteins; Skin disorder therapies
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Systemic lupus erythematosus
Most Recent Events
- 28 Sep 2026 No recent reports of development identified for phase-I development in Atopic-dermatitis in China (SC, Injection)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in Australia (SC, Injection)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in China (SC, Injection)